Tissue plasminogen activator (TPA) (Raphaeli et al., 2015) is a common treatment for cerebral infarction, but many patients do not arrive at the hospital within the limited time needed to effectively access brain-saving treatments. This evidence concerns the gene PLAT and cerebral infarction.